B cell-activating factor: Its clinical significance in multiple myeloma patients

Annals of Hematology

Volumn 91, Issue 9, 2012, Pages 1413-1418

  Fragioudaki, M ^a   Boula, A ^b   Tsirakis, G ^a   Psarakis, F ^a   Spanoudakis, M ^a   Papadakis, I S ^a   Pappa, C A ^b   Alexandrakis, M G ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b Venizelion General Hospital   (Greece)

Author keywords

B cell activating factor; Cytokines; Multiple myeloma; Prognosis

Indexed keywords

B CELL ACTIVATING FACTOR; BETA 2 MICROGLOBULIN; BORTEZOMIB; C REACTIVE PROTEIN; DEXAMETHASONE; DOXORUBICIN; INTERLEUKIN 6; LACTATE DEHYDROGENASE; MELPHALAN; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER STAGING; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B-CELL ACTIVATING FACTOR; BETA 2-MICROGLOBULIN; C-REACTIVE PROTEIN; DISEASE PROGRESSION; FEMALE; HUMANS; INTERLEUKIN-6; KAPLAN-MEIER ESTIMATE; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM PROTEINS; PROGNOSIS;

EID: 84864913379     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1470-x     Document Type: Article

References (31)

1. Landgren O (2010) Monoclonal gammopathy of undetermined significance and smoldering myeloma: new insights into pathophysiology and epidemiology. Hematology Am Soc Hematol Educ Program 2010:295-302
2. Caers J, Van Valckenborgh E, Menu E, Van Camp B, Vanderkerken K (2008) Unraveling the biology of multiple myeloma disease: cancer stemcells, acquired intracellular changes and interactionswith the surrounding micro-environment. Bull Cancer 95:301-313
3. Demchenko YN, Kuehl WM (2010) A critical role for NFκB pathway in multiple myeloma. Oncotarget 1:59-68
4. Hanamura I, Stewart J, Huang Y, Zhan F, Santra M, Sawyer J, Hollnig K, Zangarri M, Pineda-Roman M, Van Rhee F, Cavallo F, Burington B, Crowley J, Tricot G, Barlogie B, Shaughnessy JD (2006) Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 108:1724-1732
5. Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, Ambrose C, Lawton P, Bixler S, Acha-Orbea H, Valmori D, Romero P, Werner-Favre C, Zubler RH, Browning JL, Tschopp J (1999) BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 189:1747-1756
6. Hahne M, Kataoka T, Schröter M, Hofmann K, Irmler M, Bodmer JL, Schneider P, Bornand T, Holler N, French LE, Sordat B, Rimoldi D, Tschopp J (1998) APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 188:1185-1190
7. Mackay F, Schneider P (2009) Cracking the BAFF code. Nat Rev Immunol 9:491-502
8. Seshasayee D, Valdez P, Yan M, Dixit VM, Tumas D, Grewal IS (2003) Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 18:279-288
9. Thompson JS, Bixler SA, Qian F, Vora K, Scott ML, Cachero TG, Hession C, Schneider P, Sizing ID, Mullen C, Strauch K, Zafari M, Benjamin CD, Tschopp J, Browning JL, Ambrose C (2001) BAFFR, a newly identified TNF receptor that specifically interacts with BAFF. Science 293:2108-2111
10. Treml JF, Hao Y, Stadanlick JE, Cancro MP (2009) The BLyS family: toward a molecular understanding of B cell homeostasis. Cell Biochem Biophys 53:1-16
11. Novak AJ, Bram RJ, Kay NE, Jelinek DF (2002) Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood 100:2973-2979
12. Kern C, Cornuel JF, Billard C, Tang R, Rouillard D, Stenou V, Defrance T, Ajchenbaum-Cymbalista F, Simonin PY, Feldblum S, Kolb JP (2004) Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 103:679-688
13. Briones J, Timmerman JM, Hilbert DM, Levy R (2002) BLyS and BLyS receptor expression in non-Hodgkin's lymphoma. Exp Hematol 30:135-141
14. Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K, Kindsvogel W, Gross JA, Greipp PR, Jelinek DF (2004) Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 103:689-694
15. Moreaux J, Legouffe E, Jourdan E, Quittet P, Reme T, Lugagne C, Moine P, Rossi JF, Klein B, Tarte K (2004) BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 103:3148-3157
16. Jelinek DF, Darce JR (2005) Human B lymphocyte malignancies: exploitation of BlyS and APRIL and their receptors. Curr Dir Autoimmun 8:266-288
17. Tai YT, Li XF, Breitkreutz I, Song W, Neri P, Catley L, Podar K, Hideshima T, Chauhan D, Raje N, Schlossman R, Richardson P, Munshi NC, Anderson KC (2006) Role of B-cellactivating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res 66:6675-6682
18. Neri P, Kumar S, Fulciniti MT, Vallet S, Chhetri S, Mukherjee S, Tai Y, Chauhan D, Tassone P, Venuta S, Munshi NC, Hideshima T, Anderson KC, Raje N (2007) Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin Cancer Res 13:5903-5909
19. Ju S, Wang Y, Ni H, Wang X, Jiang P, Kong X, Zhong R (2009) Correlation of expression levels of BLyS and its receptors with multiple myeloma. Clin Biochem 42:387-399
20. Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, Libermann TA, Anderson KC (1996) Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 87:1104-1112
21. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC (2004) Advances in biology of multiple myeloma: clinical applications. Blood 104:607-618
22. Klein B, Tarte K, Jourdan M, Mathouk K, Moreaux J, Jourdan E, Legouffe E, De Vos J, Rossi JF (2003) Survival and proliferation factors of normal and malignant plasma cells. Int J Hematol 78:106-113
23. Hirano T (1998) Interleukin 6 and its receptor: ten years later. Int Rev Immunol 16:249-284
24. Nachbaur DM, Herold M, Maneschg A, Huber H (1991) Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters. Ann Hematol 62:54-58
25. Lauta VM (2003) A review of the cytokine network in multiple myeloma. Cancer 97:2440-2452
26. Jiang P, Yueguo W, Huiming H, Hongxiang Y, Mei W, Ju S (2009) B-lymphocyte stimulator: a new biomarker for multiple myeloma. Eur J Haematol 82:267-276
27. Yang J, Wezeman M, Zhang X, Lin P, Wang M, Qian J, Wan B, Kwak LW, Yu L, Yi Q (2007) Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis. Cancer Cell 12:252-265
28. Terpos E, Katodritou E, Roussou M, Pouli A, Michalis E, Delimpasi S, Parcharidou A, Kartasis Z, Zomas A, Symeonidis A, Viniou NA, Anagnostopoulos N, Economopoulos T, Zervas K, Dimopoulos MA, Greek Myeloma Study Group, Greece (2010) High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents. Eur J Haematol 85:114-119
29. Raje NS, Hohl Rj, Faber EA, Richardson PGG et al (2011) Phase I study of LY2127399, a human anti-BAFF antibody, and bortezomib in patients with previously treated multiple myeloma. J Clin Oncol 29, suppl; abstr 8012
30. Yaccoby S, Pennisi A, Li X, Dillon SR, Zhan F, Barlogie B, Shaughnessy JD Jr (2008) Atacicept (TACI-Ig) inhibits growth of TACI (high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts. Leukemia 22:406-413
31. Rossi JF, Moreaux J, Hose D, Requirand G, Rose M, Rouillé V, Nestorov I, Mordenti G, Goldschmidt H, Ythier A, Klein B (2009) Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study. Br J Cancer 101:1051-1058